Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma

Pharmacyclics

Status and phase: Completed; Phase 2

Conditions: Multiple Myeloma

Treatments: Drug: Dexamethasone; Drug: PCI-32765

Study type: Interventional

Funder types: Industry

Identifiers

NCT01478581

PCYC-1111-CA

PCI-32765 (Other Identifier)

Details and patient eligibility

About

The primary objective of this study is to determine the efficacy of PCI-32765, both as a single agent and in combination with dexamethasone, in subjects with relapsed or relapsed and refractory Multiple Myeloma (MM)

Full description

Bruton's tyrosine kinase (Btk) is an enzyme that is present in hematopoietic cells other than T cells and is necessary for downstream signal transduction from various hematopoietic receptors including the B cell receptor as well as some Fc, chemokine, and adhesion receptors, and is crucial for both B cell development and osteoclastogenesis. Although down-regulated in normal plasma cells, Btk is highly expressed in the malignant cells from many myeloma patients and some cell lines. PCI 32765 is a potent and specific inhibitor of Btk currently in Phase 2 clinical trials. The current study is designed and intended to determine the effects of PCI-32765 in subjects with MM.

Enrollment: 92 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosis of symptomatic MM with measurable disease, defined here as having at least one of the following:

  1. Serum monoclonal protein (M-protein) ≥0.5 g/dL as determined by serum protein electrophoresis (SPEP)
  2. Urine M-protein ≥200 mg/24 hrs
  3. Serum free light chain (FLC) assay: involved FLC level ≥10 mg/dL (≥100 mg/L) provided serum FLC ratio is abnormal

• Relapsed or relapsed and refractory MM after receiving at least 2 but no more than 5 previous lines of therapy, 1 of which must be an immunomodulator.

• Refractory myeloma (to most recent treatment) is defined as disease that is nonresponsive while on treatment or progressive disease within 60 days after the completion of preceding treatment. Nonresponsive disease is defined as either failure to achieve minimal response or development of progressive disease while on therapy.

• Men and women ≥18 years of age.

• ECOG performance status of ≤ 1.

Exclusion criteria

• Subject must not have primary refractory disease defined as disease that is nonresponsive in subjects who have never achieved a minor response (MR) or better with any therapy.
• Polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes (POEMS) syndrome, osteosclerotic myeloma, or Crow-Fukase syndrome.
• Plasma cell leukemia.
• Primary amyloidosis.
• Certain exclusions on prior therapy.
• ANC <0.75 x 10^9/L independent of growth factor support.
• Platelets <50 x 10^9/L) independent of transfusion support.
• AST or ALT ≥3.0 x upper limit of normal (ULN).
• Total bilirubin >2.5 x ULN, unless due to Gilbert's syndrome.
• Creatinine >2.5 mg/dL.
• Unable to swallow capsules or disease significantly affecting gastrointestinal function.
• Requires anti-coagulation with warfarin or a vitamin K antagonist. Requires treatment with strong CYP3A4/5 inhibitors.

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

92 participants in 4 patient groups

Cohort 1

Experimental group

Description:

PCI-32765 420 mg per day

Treatment:

Drug: PCI-32765

Cohort 2

Experimental group

Description:

PCI-32765 560 mg per day, 40 mg dexamethasone (oral) once per week

Treatment:

Drug: Dexamethasone

Drug: PCI-32765

Cohort 3

Experimental group

Description:

PCI-32765 840 mg per day

Treatment:

Drug: PCI-32765

Cohort 4

Experimental group

Description:

PCI-32765 840 mg per day, 40 mg dexamethasone (oral) once per week

Treatment:

Drug: Dexamethasone

Drug: PCI-32765